LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced that its mobile healthcare application has entered the final stage of development. The company is completing testing, optimization, and deployment preparations ahead of a planned release through the Apple App Store and Google Play. Management expects to submit the app for distribution in the coming weeks, subject to platform review and technical requirements.
This milestone represents a shift from development to public availability, giving users a direct mobile gateway to LataMed AI’s digital healthcare ecosystem. The app is designed as a primary access point for supported healthcare services and digital tools, with future functionality expected to include patient-facing tools, healthcare-provider interaction, digital communications, wellness information, and service coordination. The company views this as a scalable foundation for expanding its platform.
Mobile accessibility is particularly strategic for Latin America, where smartphones are a primary means of accessing digital services. By launching on both major app marketplaces, LataMed AI aims to offer a user-friendly interface while establishing infrastructure for future growth. This aligns with the company’s broader goal of connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and wellness organizations in an integrated digital environment.
LataMed AI continues to develop its AI-supported technologies, including CardioAI, PulmoAI, and NeuroAI. The mobile app will serve as an additional pathway for users and professionals to interact with these tools, subject to ongoing development and regulatory approvals. The company plans to evaluate additional features and integrations for future versions.
Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the importance of mobile availability: “Mobile availability is important because it provides a direct connection between users and the digital healthcare ecosystem we are building. Our objective is to create a platform that is practical, accessible, and capable of expanding.” He noted that the team is completing final testing and expects the app to be available in the coming weeks.
The company believes this release will advance its mission to improve healthcare access in Latin America. Following the launch, LataMed AI intends to continue developing new functionality and integrations. Updates will be provided as milestones are completed.
For more information, visit LataMed AI’s website or review filings with the U.S. Securities and Exchange Commission at www.sec.gov.
